GLP-1 medications are expensive due to complex manufacturing processes, patent protection, high demand, limited generic competition, and the U.S
In the same line, Fujita et al described a patient on chronic hydrocortisone who manifested symptoms of hypocortisolism after the start of exenatide therapy [33]
Regular exercise training enhances these adaptive responses, leading to elevated baseline antioxidant defenses that exceed sedentary levels
Many of these patients are also on endocrine therapy, which makes the tolerated side effect profile particularly relevant
Im not seeing super niche-use cases
When retatrutide becomes available, it may be considered for obesity or overweight with related health risks-similar to Ozempic and Mounjaro